Enigmalady777
Active member
I take 10 mg six days a week, 15 once a week.
Are you on aortic or mitral valve ?Try to simplify things. A constant daily dose is the simplest approach. Unless the INR is way out of range small changes in the dose should be made.
Try not to markedly alter your diet. From say no salad to large kale filled salad every day. Get a home testing device and your life will be much better.
I usually take meds in the morning less likely to forget. Also don’t markedly alter other meds without monitoring the INR. Most people settle down and are pretty stable. I used to need 6 mg now I use 5 per day with an INR target near 2.5+. The data for low INR for Onyx valves was not compelling unless you are a fan of higher stroke rates.
that is very surprising because warfarin usually comes on 1, 5 and 10 mgs. tablets. Maybe you could ask druggist about what’s available In your area.
Also 500mcg (0.5mg)Just for info, here in the UK Warfarin comes in 1, 3 and 5mg tablets.
My cardiologist doesn't want me to be on Warfarin after surgery. He wants to use Xarelto instead so I have to only take one pill daily and still have a fairly normal lifestyle and not worry about what to eat or not eat. Many friends of mine (even my pharmacist) is on Xarelto and are very happy with the results of keeping 2.0-2.5 INR.
I thought INR shouldn't be used to monitor anticoagulation, as it not reliable, under Xarelto (Rivaroxaban)?Many friends of mine (even my pharmacist) is on Xarelto and are very happy with the results of keeping 2.0-2.5 INR.
My surgeon also said that he will more than likely not put me on warfarin. I did come across this article which was pretty interesting about the use of Xarelto in low risk patients who has a recent AVR with a mechanical valve...
https://www.thrombosisresearch.com/article/S0049-3848(19)30530-4/fulltext
The results of this trial indicate that rivaroxaban is noninferior to warfarin for prevention of thromboembolic events among patients with AF/AFL and a bioprosthetic mitral valve. All strokes were lower with rivaroxaban.
This is one of the first trials to directly evaluate the role of a direct OAC (DOAC) in patients with mitral valve disease and atrial arrhythmias. Historically, these patients have been treated with warfarin. Although this trial has limitations (open-label design, etc.), these findings are likely to be practice changing. The only caveat is that it is unclear if the mitral valve surgery was for rheumatic heart disease, in particular mitral stenosis, where warfarin is still recommended as the OAC of choice.
[/QUOTE]..........thus Warfarin could be extinct in the next decade?
I think too that there are a lot of doctors and scientists that are performing studies and tests, with a vast greater knowledge than the consumers. It seems the consumer is always left in the dark until a breakthrough surfaces. This study of using Rivaroxaban for anticoagulant could be a game changer as it could possibly push Warfarin out the door. It is still a very new drug, but maybe they are finding that it works too well, thus Warfarin could be extinct in the next decade?
I don't think it will take a decade. We have seen the patent holder of "Coumadin" discontinue production and a few of the major manufacturers of
"Warfarin" also leave the market. The ACT market is not driven by the relatively small mechanical valve users. The big market and big money is with the a-fib and similar chronic patient. My hope is that warfarin stays around for a few more years..........I'm reminded of the saying "the devil you know is often better than the one you don't know".
Estimated XARELTO® Co-pay Cost | XARELTO® (rivaroxaban) (xarelto-us.com)
The list price of XARELTO® is $470 per month!
Just a touch more than warfarin?
[QUOTE="Superman, post: 902436, member: 697
For the record, I take warfarin, lead a normal life, consistently test between 2.5 and 3.5, and don’t worry about what I eat or drink.
I think too that there are a lot of doctors and scientists that are performing studies and tests, with a vast greater knowledge than the consumers. It seems the consumer is always left in the dark until a breakthrough surfaces. This study of using Rivaroxaban for anticoagulant could be a game changer as it could possibly push Warfarin out the door. It is still a very new drug, but maybe they are finding that it works too well, thus Warfarin could be extinct in the next decade?
Enter your email address to join: